Mologen AG appointed Dr. Ignacio Faus as member of the Executive Board and new Chief Executive Officer the company with effect from August 1, 2018. He has more than 25 years of experience in the life science industry, with invaluable experience in fundraising, organizational planning, strategic project evaluation, operational efficiency, Business Development & Licensing, etc. In 2006 he was one of the founders of PALAU PHARMA, a biopharmaceutical company in the inflammation and autoimmune disease space.

For several years he managed the investment – operational – divestment life cycle of the company, until its final sale. He has also held a number of advisory roles, consulting engagements, and Board of Directors positions in several pharmaceutical, biotechnology and private equity organizations. In his role as CEO of the company, he will be in charge of Business Development, Investor Relations & Corporate Communications, Partnering, Production, and Strategy.

Dr. Mariola Söhngen has resigned from her post as Chairwoman of the Executive Board on July 31, 2018 and will leave the Executive Board effective October 31, 2018. In the interim period from August 1, 2018 to October 31, 2018, she will provide support as an Executive Board Member without a specific area of responsibility, cooperating with Dr. Faus to ensure a smooth transition of the chairmanship. She had informed the Supervisory Board that she will not extend her position as member of the Executive Board and CEO of the company beyond her initial contract ending on October 31, 2018.